Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer

Biological Procedures Online

Volumn 19, Issue 1, 2017, Pages

  Lu, Yan ^a   Li, Shulin/SL ^b   Zhu, Shiguo/SG ^a   Gong, Yabin/YB ^a   Shi, Jun/J ^a   Xu, Ling/ L ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Circulating RNA; ctDNA; Liquid biopsy; Lung cancer; Methylation

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; RNA; UNCLASSIFIED DRUG;

BODY FLUID; CANCER PROGNOSIS; CANCER SCREENING; CPG ISLAND; DISEASE MARKER; DNA METHYLATION; DNA PURIFICATION; EPIGENETICS; GENETIC SCREENING; HISTONE MODIFICATION; HUMAN; LUNG CANCER; NEXT GENERATION SEQUENCING; PATIENT MONITORING; PROMOTER REGION; REVIEW; RNA METHYLATION; TRANSCRIPTION INITIATION SITE;

EID: 85015449978     PISSN: None     EISSN: 14809222     Source Type: Journal    
DOI: 10.1186/s12575-017-0051-8     Document Type: Review

References (110)

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA Cancer J Clin. 2016;66:7-30.
2. Secretan B, Straif K, Baan R, et al. A Review of Human Carcinogens-Part E: Tobacco, Areca Nut, Alcohol, Coal Smoke, and Salted Fish. Lancet Oncol. 2009;10:1033-4.
3. Team NLSTR, Aberle DR, Adams AM, et al. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365:395-409.
4. Patz Jr EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in Low-dose Computed Tomography Screening for Lung Cancer. JAMA Intern Med. 2014;174:269-74.
5. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer. J Thorac Oncol. 2009;4:792-801.
6. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013, Based on November 2015 SEER Data Submission, Posted to the SEER Web Site, April 2016. Bethesda: National Cancer Institute; 2016. https://seer.cancer.gov/csr/1975_2013/. Accessed 3 Feb 2017.
7. Berger SL, Kouzarides T, Shiekhattar R, et al. An Operational Definition of Epigenetics. Genes Dev. 2009;23:781-3.
8. Sharma S, Kelly TK, Jones PA. Epigenetics in Cancer. Carcinogenesis. 2010;31:27-36.
9. Baylin SB. The Cancer Epigenome: Its Origins, Contributions to Tumorigenesis, and Translational Implications. Proc Am Thorac Soc. 2012;9:64-5.
10. Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016;8:a019505.
11. Bird A. DNA Methylation Patterns and Epigenetic Memory. Genes Dev. 2002;16:6-21.
12. Prendergast GC, Ziff EB. Methylation-sensitive Sequence-Specific DNA Binding by the c-Myc Basic Region. Science. 1991;251:186-9.
13. Watt F, Molloy PL. Cytosine Methylation Prevents Binding to DNA of a HeLa Cell Transcription Factor Required for Optimal Expression of the Adenovirus Major Late Promoter. Genes Dev. 1988;2:1136-43.
14. Nan X, Ng HH, Johnson CA, et al. Transcriptional Repression by the Methyl-CpG-binding Protein MeCP2 Involves a Histone Deacetylase Complex. Nature. 1998;393:386-9.
15. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 Recruit Histone Deacetylase to Repress Transcription. Nat Genet. 1998;19:187-91.
16. Baylin SB, Jones PA. A Decade of Exploring the Cancer Epigenome - Biological and Translational Implications. Nat Rev Cancer. 2011;11:726-34.
17. Powrózek T, Krawczyk P, Nicoś M, et al. Methylation of the DCLK1 Promoter Region in Circulating Free DNA and its Prognostic Value in Lung Cancer Patients. Clin Transl Oncol. 2016;18:398-404.
18. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a Panel of Sensitive and Specific DNA Methylation Markers for Lung Adenocarcinoma. Mol Cancer. 2007;6:70.
19. Kontic M, Stojsic J, Jovanovic D, et al. Aberrant Promoter Methylation of CDH13 and MGMT Genes is Associated with Clinicopathologic Characteristics of Primary Non-small-cell Lung Carcinoma. Clin Lung Cancer. 2012;13(4):297-303.
20. Sato T, Arai E, Kohno T, et al. Epigenetic Clustering of Lung Adenocarcinomas Based on DNA Methylation Profiles in Adjacent Lung Tissue: Its Correlation with Smoking History and Chronic Obstructive Pulmonary Disease. Int J Cancer. 2014;135:319-34.
21. Hawes SE, Stern JE, Feng Q, et al. DNA Hypermethylation of Tumors from Non-small Cell Lung Cancer (NSCLC) Patients is Associated with Gender and Histologic Type. Lung Cancer. 2010;69:172-9.
22. Carvalho RH, Hou J, Haberle V, et al. Genomewide DNA Methylation Analysis Identifies Novel Methylated Genes in Non-small-cell Lung Carcinomas. J Thorac Oncol. 2013;8:562-73.
23. Walter K, Holcomb T, Januario T, et al. DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-small Cell Lung Cancer. Clin Cancer Res. 2012;18:2360-73.
24. Shinjo K, Okamoto Y, An B, et al. Integrated Analysis of Genetic and Epigenetic Alterations Reveals CpG Island Methylator Phenotype Associated with Distinct Clinical Characters of Lung Adenocarcinoma. Carcinogenesis. 2012;33:1277-85.
25. Cancer Genome Atlas Research Network. Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature. 2014;511:543-50.
26. Selamat SA, Galler JS, Joshi AD, et al. DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma in Situ, and Lung Adenocarcinoma. PLoS One. 2011;6:e21443.
27. Brock MV, Hooker CM, Ota-Machida E, et al. DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer. N Engl J Med. 2008;358:1118-28.
28. Sato T, Arai E, Kohno T, et al. DNA Methylation Profiles at Precancerous Stages Associated with Recurrence of Lung Adenocarcinoma. PLoS One. 2013;8:e59444.
29. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A Prognostic DNA Methylation Signature for Stage I Nonsmall-cell Lung Cancer. J Clin Oncol. 2013;31:4140-7.
30. Robles AI, Arai E, Mathé EA, et al. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. J Thorac Oncol. 2015;10:1037-48.
31. Juergens RA, Wrangle J, Vendetti FP, et al. Combination Epigenetic Therapy has Efficacy in Patients with Refractory Advanced Non-small Cell Lung Cancer. Cancer Discov. 2011;1(7):598-607.
32. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine Content of DNA from Human Tumors. Nucleic Acids Res. 1983;11:6883-94.
33. Pfeifer GP, Rauch TA. DNA Methylation Patterns in Lung Carcinomas. Semin Cancer Biol. 2009;19:181-7.
34. Feinberg AP, Vogelstein B. Hypomethylation Distinguishes Genes of some Human Cancers from their Normal Counterparts. Nature. 1983;301:89-92.
35. Feinberg AP, Vogelstein B. Hypomethylation of Ras Oncogenes in Primary Human Cancers. Biochem Biophys Res Commun. 1983;111:47-54.
36. Rauch TA, Zhong X, Wu X, et al. High-resolution Mapping of DNA Hypermethylation and Hypomethylation in Lung Cancer. Proc Natl Acad Sci U S A. 2008;105:252-7.
37. El Messaoudi S, Rolet F, Mouliere F, et al. Circulating Cell Free DNA: Preanalytical Considerations. Clin Chim Acta. 2013;424:222-30.
38. Warton K, Lin V, Navin T, et al. Methylation-capture and Next-generation Sequencing of Free Circulating DNA from Human Plasma. BMC Genomics. 2014;15:476.
39. Diehl F, Schmidt K, Choti MA, et al. Circulating Mutant DNA to Assess Tumor Dynamics. Nat Med. 2008;14:985-90.
40. Jahr S, Hentze H, Englisch S, et al. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for their Origin from Apoptotic and Necrotic Cells. Cancer Res. 2001;61:1659-65.
41. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2007;1775:181-232.
42. Schwarzenbach H, Alix-Panabières C, Müller I, et al. Cell-free Tumor DNA in Blood Plasma as a Marker for Circulating Tumor Cells in Prostate Cancer. Clin Cancer Res. 2009;15:1032-8.
43. Shaw JA, Brown J, Coombes RC, et al. Circulating Tumor Cells and Plasma DNA Analysis in Patients with Indeterminate Early or Metastatic Breast Cancer. Biomark Med. 2011;5:87-91.
44. Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in Exosomes: A Novel Biomarker in Cancer Detection. Cell Res. 2014;24:766-9.
45. Balgkouranidou I, Chimonidou M, Milaki G, et al. SOX17 Promoter Methylation in Plasma Circulating Tumor DNA of Patients with Non-small Cell Lung Cancer. Clin Chem Lab Med. 2016;54:1385-93.
46. Konecny M, Markus J, Waczulikova I, et al. The Value of SHOX2 Methylation Test in Peripheral Blood Samples Used for the Differential Diagnosis of Lung Cancer and other Lung Disorders. Neoplasma. 2016;63:246-53.
47. Zhang Y, Wang R, Song H, et al. Methylation of Multiple Genes as a Candidate Biomarker in Non-small Cell Lung Cancer. Cancer Lett. 2011;303:21-8.
48. Margolin G, Petrykowska HM, Jameel N, et al. Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-based Diagnostic Development. J Mol Diagn. 2016;18:283-98.
49. Gainetdinov IV, Kapitskaya KY, Rykova EY, et al. Hypomethylation of Human-specific Family of LINE-1 Retrotransposons in Circulating DNA of Lung Cancer Patients. Lung Cancer. 2016;99:127-30.
50. Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. RARβ2 Gene Methylation Level in the Circulating DNA from Blood of Patients with Lung Cancer. Eur J Cancer Prev. 2011;20:453-5.
51. Zhu ZZ, Sparrow D, Hou L, et al. Repetitive Element Hypomethylation in Blood Leukocyte DNA and Cancer Incidence, Prevalence, and Mortality in Elderly Individuals: The Normative Aging Study. Cancer Causes Control. 2011;22:437-47.
52. Woodson K, Mason J, Choi SW, et al. Hypomethylation of p53 in Peripheral Blood DNA is Associated with the Development of Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:69-74.
53. Russo AL, Thiagalingam A, Pan H, et al. Differential DNA Hypermethylation of Critical Genes Mediates the Stage-specific Tobacco Smoke-induced Neoplastic Progression of Lung Cancer. Clin Cancer Res. 2005;11:2466-70.
54. Wang W, Feng X, Duan X, et al. Establishment of Two Data Mining Models of Lung Cancer Screening Based on Three Gene Promoter Methylations Combined with Telomere Damage. Int J Biol Markers. 2016;24:0.
55. Wang L, Aakre JA, Jiang R, et al. Methylation Markers for Small Cell Lung Cancer in Peripheral Blood Leukocyte DNA. J Thorac Oncol. 2010;5:778-85.
56. Leng S, Do K, Yingling CM, et al. Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment. Clin Cancer Res. 2012;18:3387-95.
57. Xiao P, Chen JR, Zhou F, et al. Methylation of P16 in Exhaled Breath Condensate for Diagnosis of Non-small Cell Lung Cancer. Lung Cancer. 2014;83:56-60.
58. Lee TH, Montalvo L, Chrebtow V, et al. Quantitation of Genomic DNA in Plasma and Serum Samples: Higher Concentrations of Genomic DNA Found in Serum Than in Plasma. Transfusion. 2001;41:276-82.
59. Devonshire AS, Whale AS, Gutteridge A, et al. Towards Standardisation of Cell-free DNA Measurement in Plasma: Controls for Extraction Efficiency, Fragment Size Bias and Quantification. Anal Bioanal Chem. 2014;406:6499-512.
60. Mauger F, Dulary C, Daviaud C, et al. Comprehensive Evaluation of Methods to Isolate, Quantify, and Characterize Circulating Cell-free DNA from Small Volumes of Plasma. Anal Bioanal Chem. 2015;407:6873-8.
61. Page K, Guttery DS, Zahra N, et al. Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids. PLoS One. 2013;8:e77963.
62. Clark SJ, Harrison J, Paul CL, et al. High Sensitivity Mapping of Methylated Cytosines. Nucleic Acids Res. 1994;22:2990-7.
63. Hernández HG, Tse MY, Pang SC, et al. Optimizing Methodologies for PCR-based DNA Methylation Analysis. Biotechniques. 2013;55:181-97.
64. Holmes EE, Jung M, Meller S, et al. Performance Evaluation of Kits for Bisulfite-conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. PLoS One. 2014;9:e93933.
65. Hayatsu H, Shiragami M. Reaction of Bisulfite with the 5-hydroxymethyl Group in Pyrimidines and in Phage DNAs. Biochemistry. 1979;18:632-7.
66. Weber M, Davies JJ, Wittig D, et al. Chromosome-wide and Promoter-specific Analyses Identify Sites of Differential DNA Methylation in Normal and Transformed Human Cells. Nat Genet. 2005;37:853-62.
67. Jeuken JW, Cornelissen SJ, Vriezen M, et al. MS-MLPA: An Attractive Alternative Laboratory Assay for Robust, Reliable, and Semiquantitative Detection of MGMT Promoter Hypermethylation in Gliomas. Lab Invest. 2007;87:1055-65.
68. Huang ZH, Hu Y, Hua D, et al. Quantitative Analysis of Multiple Methylated Genes in Plasma for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Exp Mol Pathol. 2011;91:702-7.
69. Sun FK, Fan YC, Zhao J, et al. Detection of TFPI2 Methylation in the Serum of Hepatocellular Carcinoma Patients. Dig Dis Sci. 2012;58:1010-5.
70. Liu F, Killian JK, Yang M, et al. Epigenomic Alterations and Gene Expression Profiles in Respiratory Epithelia Exposed to Cigarette Smoke Condensate. Oncogene. 2010;29:3650-64.
71. Georgiadis P, Hebels DG, Valavanis I, et al. Omics for Prediction of Environmental Health Effects: Blood Leukocyte-based Cross-omic Profiling Reliably Predicts Diseases Associated with Tobacco Smoking. Sci Rep. 2016;6:20544.
72. Baglietto L, Ponzi E, Haycock P, et al. DNA Methylation Changes Measured in Pre-diagnostic Peripheral Blood Samples are Associated with Smoking and Lung Cancer Risk. Int J Cancer. 2017;140:50-61.
73. Gao X, Zhang Y, Breitling LP, et al. Tobacco Smoking and Methylation of Genes Related to Lung Cancer Development. Oncotarget. 2016;7:59017-28.
74. Davis A, Tao MH, Chen J, et al. No association between global DNA methylation in peripheral blood and lung cancer risk in nonsmoking women: results from a multicenter study in Eastern and Central Europe. Eur J Cancer Prev. 2016. doi:10.1097/CEJ.0000000000000244.
75. Vineis P, Chuang SC, Vaissière T, et al. DNA Methylation Changes Associated with Cancer Risk Factors and Blood Levels of Vitamin Metabolites in a Prospective Study. Epigenetics. 2011;6:195-201.
76. Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA Methylation is a Biomarker for the Diagnosis of Lung Cancer in Plasma. J Thorac Oncol. 2011;6:1632-8.
77. Weiss G, Schlegel A, Kottwitz D, et al. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. J Thorac Oncol. 2017;12(1):77-84.
78. Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Potentialities of Aberrantly Methylated Circulating DNA for Diagnostics and Post-treatment Follow-up of Lung Cancer Patients. Lung Cancer. 2013;81:397-403.
79. Begum S, Brait M, Dasgupta S, et al. An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-free Serum DNA. Clin Cancer Res. 2011;17:4494-503.
80. Ramirez JL, Sarries C, de Castro PL, et al. Methylation Patterns and K-ras Mutationsin Tumor and Paired Serum of Resected Non-small Cell Lung Cancer Patients. Cancer Lett. 2003;193:207-16.
81. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of Aberrant Promoter Hypermethylation of Tumor Suppressor Genes in Serum DNA from Non-small Cell Lung Cancer Patients. Cancer Res. 1999;59:67-70.
82. Bearzatto A, Conte D, Frattini M, et al. p16(INK4A) Hypermethylation Detected by Fluorescent Methylation-specific PCR in Plasma from Non-small Cell Lung Cancer. Clin Cancer Res. 2002;8:3782-7.
83. An Q, Liu Y, Gao Y, et al. Detection of p16 Hypermethylation in Circulating Plasma DNA of Non-small Cell Lung Cancer Patients. Cancer Lett. 2002;188:109-14.
84. Usadel H, Brabender J, Danenberg KD, et al. Quantitative Adenomatouspolyposiscoli Promoter Methylation Analysis in Tumor Tissue, Serum, and Plasma DNA of Patients with Lung Cancer. Cancer Res. 2002;62:371-5.
85. Zhang Y, Miao Y, Yi J, et al. Frequent Epigenetic Inactivation of Deleted in Lung and Esophageal Cancer 1 Gene by Promoter Methylation in Non-small-cell Lung Cancer. Clin Lung Cancer. 2010;11:264-70.
86. Balgkouranidou I, Chimonidou M, Milaki G, et al. Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Cell-free DNA Provides Prognostic Information in Nonsmall Cell Lung Cancer. Br J Cancer. 2014;110:2054-62.
87. Schmidt B, Beyer J, Dietrich D, et al. Quantification of Cell-free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-small Cell (NSCLC) and Small-cell Lung Cancer (SCLC) Patients. PLoS One. 2015;10:e0118195.
88. Ramirez JL, Rosell R, Taron M, et al. 14-3-3sigma Methylation in Pretreatment Serum Circulating DNA of Cisplatin-plus-gemcitabine-treated Advanced Non-smallcell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. J Clin Oncol. 2005;23:9105-12.
89. Wang H, Zhang B, Chen D, et al. Real-time Monitoring Efficiency and Toxicity of Chemotherapy in Patients with Advanced Lung Cancer. Clin Epigenetics. 2015;7:119.
90. Salazar F, Molina MA, Sanchez-Ronco M, et al. Firstline Therapy and Methylation Status of CHFR in Serum Influence Outcome to Chemotherapy Versus EGFR Tyrosine Kinase Inhibitors as Second-line Therapy in Stage IV Non-small-cell Lung Cancer Patients. Lung Cancer. 2011;72:84-91.
91. Desrosiers R, Friderici K, Rottman F. Identification of Methylated Nucleosides in Messenger RNA from Novikoff Hepatoma Cells. Proc Natl Acad Sci U S A. 1974;71:3971-5.
92. Rottman F, Shatkin AJ, Perry RP. Sequences Containing Methylated Nucleotides at the 5′ Termini of Messenger RNAs: Possible Implications for Processing. Cell. 1974;3:197-9.
93. Kellner S, Burhenne J, Helm M. Detection of RNA Modifications. RNA Biol. 2010;7:237-47.
94. Behm-Ansmant I, Helm M, Motorin Y. Use of Specific Chemical Reagents for Detection of Modified Nucleotides in RNA. J Nucleic Acids. 2011;2011:408053.
95. Kariko K, Buckstein M, Ni H, et al. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity. 2005;23:165-75.
96. So EY, Ouchi T. The Application of Toll Like Receptors for Cancer Therapy. IntJ Biol Sci. 2010;6:675-81.
97. Zhou Q, Zhu K, Cheng H. Toll-like Receptors in Human Papillomavirus Infection. Arch Immunol Ther Exp (Warsz). 2013;61:203-15.
98. Shcheblyakov DV, Logunov DY, Tukhvatulin AI, et al. Toll-like Receptors (TLRs): the Role in Tumor Progression. Acta Nat. 2010;2:21-9.
99. Yang L, Ma YM, Han WX, et al. Proteinase-activated Receptor 2 Promotes Cancer Cell Migration Through RNA Methylation-mediated Repression of miR-125b. J Biol Chem. 2015;290:26627-37.
100. Zhang C, Zhi WI, Lu H, et al. Hypoxia-Inducible Factors Regulate Pluripotency Factor Expression by ZNF217- and ALKBH5-mediated Modulation of RNA Methylation in Breast Cancer Cells. Oncotarget. 2016;7:64527-42.
101. Muraoka T, Soh J, Toyooka S, et al. The Degree of MicroRNA-34b/c Methylation in Serum-circulating DNA is Associated with Malignant Pleural Mesothelioma. Lung Cancer. 2013;82:485-90.
102. Schaefer M, Hagemann S, Hanna K, et al. Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines. Cancer Res. 2009;69:8127-32.
103. Moudra A, Hubackova S, Machalova V, et al. Dynamic Alterations of Bone Marrow Cytokine Landscape of Myelodysplastic Syndromes Patients Treated with 5-azacytidine. Oncoimmunology. 2016;5:e1183860.
104. Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an Epigenetic Hallmark of Melanoma. Cell. 2012;150:1135-46.
105. Huang W, Qi CB, Lv SW, et al. Determination of DNA and RNA Methylation in Circulating Tumor Cells by Mass Spectrometry. Anal Chem. 2016;88:1378-84.
106. Powrózek T, Krawczyk P, Kucharczyk T, et al. Septin 9 Promoter Region Methylation in Free Circulating DNApotential Role in Noninvasive Diagnosis of Lung Cancer: Preliminary Report. Med Oncol. 2014;31:917.
107. Levine ME, Hosgood HD, Chen B, et al. DNA Methylation Age of Blood Predicts Future Onset of Lung Cancer in the Women’s Health Initiative. Aging (Albany NY). 2015;7:690-700.
108. Hsu HS, Chen TP, Hung C, et al. Characterization of a Multiple Epigenetic Marker Panel for Lung Cancer Detection and Risk Assessment in Plasma. Cancer. 2007;110:2019-26.
109. Matthias W, Klemens V, Ulrike K, et al. Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD. EBioMedicine. 2015;2:929-36.
110. Zhang Y, Breitling LP, Balavarca Y, et al. Comparison and Combination of Blood DNA Methylation at Smoking-associated Genes and at Lung Cancer-related Genes in Prediction of Lung Cancer Mortality. Int J Cancer. 2016;139:2482-92.